Efficacy of Recombinant Human Endostatin Combined with TP Regimen in the Treatment of Ovarian Cancer

LIU Guo-hua

Abstract：Objective:To study the curative effect of Recombinant Human Endostatin combined with Docetaxel and Cisplatin(TP regimen) in the treatment of ovarian cancer.Method:From April 2010 to January 2011 in our hospital,38 cases with ovarian cancer,according to random number table they were randomly divided into observation group(n=19) and control group(n=19).Patients in observation group were treated by Recombinant Human Endostatin combined with TP scheme,patients in control group were alone given TP regimen,compared curative effect of two treatment methods and hematological indexes.Result:The observation group’s CR accounting and the effective rate were 52.6%(10/19) and 89.5%(17/19),were significantly higher than those in control group of 21.1%(4/19) and 57.9%(11/19),the differences were statistically significant(P<0.05).The hemoglobin,white cells and platelets of observation group were (9.86±3.48)g/100 ml, (3.62±1.19)×103/m3,(8.83±2.58)×104/m3,were significantly higher than those in control group (7.13±2.14)g/100 ml,(2.54±0.76)×103/m3 and (6.56±1.87)×104/m3,the differences were statistically significant(P<0.05).Conclusion:The efficacy Recombinant Human Endostatin regimen combined with TP regimen in the treatment of ovarian cancer is significantly,can alleviate the patients clinical symptoms.It has well tolerated and with relatively low toxicity,security is good,is worthy of recommendation.